BSI response to pre-print from The Lancet on the dosing schedule for the AstraZeneca/Oxford COVID-19 vaccine
BSI response to Germany’s vaccine committee recommendation to only give the AstraZeneca/Oxford COVID-19 vaccine to people aged under 65.
Alopecia UK has joined Connect Immune Research, an initiative designed to bring about a critical change in the way autoimmune conditions are researched. The BSI is a supporting partner of this initiative, along founding members JDRF, the MS Society and Versus Arthritis.
This statement is aimed at people who either have a medical condition which means their immune system doesn’t function optimally or people who take medication that suppresses their immune system.
British Society for Immunology statement in response to the approval of the Moderna COVID-19 vaccine in the UK.
The British Society for Immunology has produced a statement that lays out our position on the announcements around change of dosing schedule for the two approved COVID-19 vaccines.
British Society for Immunology statement in response to news of approval of Oxford University/AstraZeneca COVID-19 vaccine for use in UK
British Society for Immunology response to reports of two allergic reactions following COVID-19 vaccination
British Society for Immunology response to COVID-19 vaccine rollout on NHS
British Society for Immunology response to The Lancet paper on interim phase 3 trial results for the University of Oxford/AstraZeneca COVID-19 vaccine
BSI response to announcement that the Pfizer-BioNTech COVID-19 vaccine has been approved for use in the UK.
British Society for Immunology response to interim phase 3 results from the AstraZeneca/University of Oxford trial for the ChAdOx1 nCoV-19 vaccine against COVID-19.
British Society for Immunology response to phase 2/3 results from the AstraZeneca/University of Oxford trial for theChAdOx1 nCoV-19 vaccine against COVID-19
Press release on BSI report on the ageing immune system and COVID-19
BSI response to new pre-print study from UK-CIC researchers suggesting cellular immunity against SARS-CoV-2 is present six months after asymptomatic or mild/moderate COVID-19 infection.